Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Casi Pharmaceuticals Inc (CASI)

Casi Pharmaceuticals Inc (CASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish Stocktwits - Thu Apr 3, 2025

The company said that its special committee of the board of directors will evaluate the proposed transaction.

CASI : 0.9900 (+3.45%)
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company ACCESS Newswire - Thu Apr 3, 2025

BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 0.9900 (+3.45%)
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results ACCESS Newswire - Mon Mar 31, 2025

BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 0.9900 (+3.45%)
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia ACCESS Newswire - Mon Jan 6, 2025

BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and...

CASI : 0.9900 (+3.45%)
Wall Street - Nasdaq Times Square
Nasdaq Futures Fall as Micron’s Sales Outlook Disappoints, U.S. GDP Data and Nike Earnings in Focus Barchart - Thu Jun 27, 2024

September Nasdaq 100 E-Mini futures (NQU24) are trending down -0.23% this morning as an underwhelming sales forecast from chipmaker Micron weighed on sentiment, while investors awaited a flurry of U.S....

WHR : 86.12 (-1.16%)
AAPL : 246.86 (-3.39%)
HMB.S.DX : 176.700 (+1.00%)
MKC : 67.83 (+1.18%)
NQU24 : 19,808.01s (-0.21%)
USB : 54.38 (-0.04%)
IP : 41.66 (-3.90%)
MU : 365.03 (+0.63%)
NKE : 63.63 (-1.16%)
CASI : 0.9900 (+3.45%)
LEVI : 20.96 (-3.68%)
AYI : 309.67 (-3.36%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES PR Newswire - Fri Aug 11, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 0.9900 (+3.45%)
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals PR Newswire - Tue Aug 1, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 0.9900 (+3.45%)
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS PR Newswire - Wed May 17, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 0.9900 (+3.45%)
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022 PR Newswire - Wed Apr 26, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 0.9900 (+3.45%)
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS PR Newswire - Wed Apr 26, 2023

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...

CASI : 0.9900 (+3.45%)

Barchart Exclusives

Should You Buy the Dip in 3M Stock Today? Barchart - 6 minutes ago
3M stock sinks on mixed earnings and muted future guidance. Here’s why investors should practice caution in buying MMM shares on the post-earnings weakness. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot